Matritech's cervical cancer test wins US patent:
This article was originally published in Clinica
Executive Summary
Matritech has received a US patent covering its NMP179 protein marker test for cervical cancer. The test is based on the company's Nuclear Matrix Protein (NMP) technology, which correlates levels of NMPs in body fluids to the presence of cancer. It has already shown promising results in recent studies (see Clinica No 840, p 16). The test could improve cancer detection in the early stages when the rate of survival is greater than 90% and also reduce the cost and discomfort associated with traditional Pap smear follow-up procedures such as colposcopy, according to Matritech of Newton, Massachusetts.
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.